MindBio Therapeutics (CNSX:MBIO) Eyes Senior Exchange Dual Listing
Multiple Phase 2B trials currently dosing, Positive Trial Data and Phase 3 Plans underway.
Read issue →Breakthrough in Women's Health CNS drug research, multiple PMS, PMDD clinical trials Approved.
World First: Psychedelic drug trials assessing PK AND PD effects over key stages of menstrual cycle
Read issue →A Surprising Sleep Discovery in Microdosing research published in Nature's Translational Psychiatry
LSD increases sleep duration the day after microdosing
Read issue →Take home microdosing begins in Phase 2B trial
World first Phase 2B take-home LSD trial in depression begins
Read issue →MindBio Advances take-home Microdosing of MB22001 into Phase 2B Clinical Trials in Major Depressive Disorder.
Final regulatory approval has been granted for this landmark follow on trial
Read issue →Breakthrough Results: MB22001 Microdosing Trial Shows Significant Positive Results in Major Depressive Disorder
Positive depression data unveiled in world first government approved take home microdosing clinical trial
Read issue →MINDBIO (CNSX:MBIO) COMPLETES WORLD FIRST TAKE HOME PHASE 2 MICRODOSING DEPRESSION TRIAL
Hi I am delighted to share with you that MindBio Therapeutics Corp (CNSX: MBIO) has completed its landmark Phase 2a take…
Read issue →Take-home Microdosing (MB22001) for Depression: It's now legally being tested out in the community in these clinical trials
Hi It's a very small dose of a proprietary form of LSD (lysergic acid diethylamide) for take-home microdosing…
Read issue →